Rej. Tenberge et al., CONDITIONAL INVOLVEMENT OF MUSCARINIC M(1) RECEPTORS IN VAGALLY MEDIATED CONTRACTION OF GUINEA-PIG BRONCHI, Naunyn-Schmiedeberg's archives of pharmacology, 352(2), 1995, pp. 173-178
The involvement of ganglionic muscarinic M(1) receptors in vagally ind
uced bronchoconstriction in guinea-pig airways is controversial. There
fore, we studied the effects of the M(1)-selective muscarinic receptor
antagonist pirenzepine on vagus nerve (VNS, preganglionic) and electr
ical field stimulation (EFS, postganglionic)-induced contractions of t
he guinea-pig main bronchus under various experimental conditions. Usi
ng identical stimulation parameters for VNS and EFS (8V, 30 Hz, 0.5 ms
, 5s every min), the amplitude of the VNS-induced twitch contractions
was 30.4% of the EFS-induced responses, and pirenzepine showed 2.3-fol
d selectivity (pIC(50)-values 6.45 and 6.09, respectively) to inhibit
vagally induced contractions. With the stimulation frequency for EFS l
owered to match contraction levels obtained using VNS, pirenzepine was
equipotent to inhibit both types of response at M(1) receptor-selecti
ve concentrations, suggesting that M(1) receptors are not involved. By
contrast, when the stimulation episode was prolonged until plateau co
ntraction (10-20 s), in the presence of the nicotinic antagonist hexam
ethonium (5 mu M), the M(2) receptor antagonist AQ-RA 741 (0.1 mu M) a
nd the beta-adrenoceptor antagonist timolol (1 mu M), and again using
matched VNS- and EFS-induced contraction levels, pirenzepine inhibited
nerve stimulation-evoked responses in a biphasic manner, yielding pIC
(50)-values of 8.12 (indicative of M(1) receptor blockade) and 6.43 (i
ndicative of M(3) receptor blockade) for the first and second phase, r
espectively, while postganglionic stimulation showed a purely monophas
ic inhibition (pIC(50) = 6.32). These results show that facilitatory m
uscarinic M(1) receptors are involved in vagally mediated contraction
of guinea-pig bronchi, under conditions of elevated neurotransmission
and partial nicotinic receptor blockade.